Trial
NCT01418001
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
National Comprehensive Cancer Network; University of California, Los Angeles; Washington University School of Medicine; Northwestern University
Condition
Sarcoma
Intervention
Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
Why stopped
Lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-11